智通财经APP讯,歌礼制药-B(01672)公布,已于2026年2月10日完成配售合共6925.6万股股份,每股配售价12.18港元,净筹约8.35亿港元,约90%建议用于治疗肥胖症的小分子口服GLP-1受体激动剂ASC30的全球III期临床试验的准备、基础工作及启动,约10%建议用作营运资金及其他一般公司用途。
智通财经APP讯,歌礼制药-B(01672)公布,已于2026年2月10日完成配售合共6925.6万股股份,每股配售价12.18港元,净筹约8.35亿港元,约90%建议用于治疗肥胖症的小分子口服GLP-1受体激动剂ASC30的全球III期临床试验的准备、基础工作及启动,约10%建议用作营运资金及其他一般公司用途。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.